We are live on ! Find out more
MRTX

Mirati Therapeutics, Inc. Common Stock
MRTX

Delisted

MRTX was delisted on the 22nd of January, 2024.

Back to rankings

43 hedge funds and large institutions have $140M invested in Mirati Therapeutics, Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2% less funds holding

Funds holding: 44 → 43 (-1)

14% less capital invested

Capital invested by funds: $162M → $140M (-$22.1M)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

29% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 14

Holders
43
Holders Change
-1
Holders Change %
-2.27%
% of All Funds
1.25%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
6
Increased
10
Reduced
14
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$1.74M
2
Northern Trust
Northern Trust
Illinois
+$1.19M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$560K
4
IAM
Integre Asset Management
New York
+$425K
5
State Street
State Street
Massachusetts
+$116K

Top Sellers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
-$3M
2
DCM
Driehaus Capital Management
Illinois
-$1.37M
3
Goldman Sachs
Goldman Sachs
New York
-$246K
4
Jane Street
Jane Street
New York
-$244K
5
SIM
Spark Investment Management
New York
-$231K
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$184K – – –
TA
27
Teachers Advisors
New York
$180K – – –
U
28
UBS
Switzerland
$174K -$87K -4,662 -32%
Royal Bank of Canada
29
Royal Bank of Canada
Ontario, Canada
$167K +$9.33K +500 +6%
TRCT
30
Tower Research Capital (TRC)
New York
$98K +$81.3K +4,356 +354%
NFA
31
Nationwide Fund Advisors
Ohio
$92K -$93 -5 -0.1%
AIG
32
American International Group
New York
$82.1K -$56 -3 -0.1%
FANJ
33
Financial Architects (New Jersey)
New Jersey
$53K +$56K +3,000 New
BA
34
BlackRock Advisors
Delaware
$52K – – –
SO
35
STRS Ohio
Ohio
$42K – – –
Wells Fargo
36
Wells Fargo
California
$18K -$3.36K -180 -15%
AllianceBernstein
37
AllianceBernstein
Tennessee
$7K -$7.46K -400 -50%
GSC
38
Ground Swell Capital
South Carolina
$5K +$5.09K +273 New
Barclays
39
Barclays
United Kingdom
$4K +$1.47K +79 +50%
Citigroup
40
Citigroup
New York
$4K +$3.53K +189 +310%
BNP Paribas Financial Markets
41
BNP Paribas Financial Markets
France
$2.1K +$2.24K +120 New
BRWM
42
B. Riley Wealth Management
Tennessee
$1K – – –
Manulife (Manufacturers Life Insurance)
43
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$63 -$27.9K -1,494 -29%
Jane Street
44
Jane Street
New York
– -$244K -12,201 Closed
SIM
45
Spark Investment Management
New York
– -$231K -11,600 Closed
Two Sigma Investments
46
Two Sigma Investments
New York
– -$226K -11,279 Closed
ARTA
47
A.R.T. Advisors
New York
– -$218K -10,931 Closed
SG Americas Securities
48
SG Americas Securities
New York
– -$182K -9,116 Closed
Bank of America
49
Bank of America
North Carolina
– -$110K -5,479 Closed
VFA
50
Virtus Fund Advisers
Connecticut
– -$12K -612 Closed
1
2

MRTX Hedge Fund Activity: Q3 2014 in Review

43 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q3 2014, worth a combined $140M — down 14% from $162M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of MRTX and 6 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 10 added.

The largest buyer was JP Morgan Chase, opening a new position worth an estimated $1.74M. The largest seller was Franklin Resources, cutting an estimated $3M.

  • 43 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q3 2014, down from 44 in Q2 2014.
  • Funds reported $140M of Mirati Therapeutics, Inc. Common Stock stock for Q3 2014, down 14% quarter-over-quarter.
  • 6 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q3 2014 and 7 closed out, a net change of -1 holder.
  • The largest Mirati Therapeutics, Inc. Common Stock buyer in Q3 2014 was JP Morgan Chase, an estimated $1.74M added.
  • The largest Mirati Therapeutics, Inc. Common Stock seller in Q3 2014 was Franklin Resources, an estimated $3M sold.

Based on aggregated 13F filings for Q3 2014.